Page 2 - Astrazeneca

AstraZeneca India surrenders marketing approval of prostate cancer drug

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..

AstraZeneca gets nod to import, sell hyperkalaemia treatment drug in India

Sodium zirconium cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients

AstraZeneca's cancer drug tops list of new brands launched in 2024

Five of top 20 drug introductions target cancer, reflecting its rising incidence in India

AstraZeneca reports better than expected profit on higher cancer drug sales

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts surveyed by Bloomberg

AstraZeneca scraps $558 mn UK investment plans citing cut in govt support

The decision to ditch the development of an existing facility in the Speke area of Liverpool comes at a time when Prime Minister Keir Starmer is pushing hard to drum up investment in Britain

AstraZeneca Pharma share price rises 3% on CDSCO nod for Eculizumab

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO

AstraZeneca and Merck drugs set to shake up treatment of liver cancer

Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress of liver cancer when combined with other drugs and a local treatment

Focus on next-gen therapeutics, AstraZeneca to restructure biopharma unit

Global portfolio includes over 20 novel therapies; development follows reports of layoffs affecting over 125 employees within the unit

AstraZeneca withdraws EU application for experimental lung cancer drug

Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not significantly improve overall survival for patients

British firms downbeat about China business despite stimulus: Survey

Doing business in China had become tougher for five consecutive years and only 41 per cent of its members were expecting to have a better time next year, the survey said

AstraZeneca asthma drug more effective than steroids during attacks: Study

The researchers found that Fasenra can be more effective than the oral corticosteroid prednisolone when injected during an attack, also called an exacerbation, which can involve symptoms such

AstraZeneca Pharma gets nod for sale, distribution of cancer drug Lynparza

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults

AstraZeneca Pharma shares up on CDSCO nod for cancer drug Lynparza

This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients with advanced or recurrent endometrial cancer, said AstraZeneca Pharma

AstraZeneca Pharma to launch COPD drug in January 2025; stock up 3%

Shares of AstraZeneca Pharma India rose 2.98 per cent at Rs 6,588.35 per share on the BSE in Tuesday's intraday deals

AstraZeneca Pharma India results: Q2FY25 net profit falls 27% to Rs 38 cr

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second quarter ended on September 30, 2024. The drug firm reported a net profit of Rs 52 crore in the July-September quarter of last fiscal. Revenue from operations stood at Rs 408 crore for the period under review compared with Rs 311 crore in the year-ago period, the firm said in a regulatory filing. Shares of the company ended 3.74 per cent lower at Rs 7,133.10 apiece on the BSE.

AstraZeneca raises expectation for next year profits after Q3 performance

AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast of a mid-teens percentage at constant currency rates for both revenue

Dharma Productions-Adar Poonawalla deal gives quest for scale a chance

Biz of making films and shows needs more such tie-ups if it is to scale up

AstraZeneca's Chennai, Bengaluru centres to drive 2030 global tech roadmap

The Global Innovation and Technology Centre (GITC) in Chennai will be hiring around 1,300 people in the next 18 months, while another 900 will be hired in Bengaluru

Policy support important as India largely an out-of-pocket market: Panchal

AstraZeneca Pharma India Managing Director and Country President, Sanjeev Panchal, talks to Shine Jacob about the company's future plans in an interview

AstraZeneca Pharma gets CDSCO nod to import Durvalumab solutions

The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India